Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Terminated 3Completed 2

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Hepatocellular 3

Interventions

Cyclophosphamide 391Carboplatin 345pembrolizumab 332Gemcitabine 332Cisplatin 328Paclitaxel 298Radiotherapy 297Docetaxel 288Bevacizumab 254Rituximab 234Capecitabine 224Nivolumab 222Dexamethasone 206Fluorouracil 191fludarabine 178Oxaliplatin 178Pemetrexed 154Doxorubicin 153Irinotecan 149Leucovorin 145Etoposide 144Cytarabine 134Cetuximab 131fludarabine phosphate 129Bortezomib 129Lenalidomide 126Erlotinib Hydrochloride 121Filgrastim 120Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × TLC 388 × Clear all
NCT02267213 2019-02-26

Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma

Taiwan Liposome Company

Phase 2 Terminated
29 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT03035006 2018-11-06

Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis

Taiwan Liposome Company

Phase 1/2 Terminated
1 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT01425996 2018-08-21

A Dose-escalation Study of LipotecanĀ® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma

Taiwan Liposome Company

Phase 1/2 Terminated
3 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚔